The epidemiology and societal costs of myasthenia gravis in Norway: A non‐interventional study using national registry data

Abstract

AbstractBackground and purposeWith the emergence of new treatment options for myasthenia gravis (MG), there is a need for information regarding epidemiology, healthcare utilization, and societal costs to support economic evaluation and identify eligible patients. We aimed to enhance the understanding of these factors using nationwide systematic registry data in Norway.MethodsWe received comprehensive national registry data from five Norwegian health‐ and work‐related registries. The annual incidence and prevalence were estimated for the period 2013–2021 using nationwide hospital and prescription data. The direct, indirect (productivity losses) and intangible costs (value of lost life‐years [LLY] and health‐related quality of life [HRQoL]) related to MG were estimated over a period of 1 year.ResultsIn 2021, the incidence of MG ranged from 15 to 16 cases per year per million population depending on the registry used, while the prevalence varied between 208.9 and 210.3 per million population. The total annual societal costs of MG amounted to EUR 24,743 per patient, of which EUR 3592 (14.5%) were direct costs, EUR 8666 (35.0%) were productivity loss, and EUR 12,485 (50.5%) were lost value from LLY and reduced HRQoL.ConclusionThe incidence and prevalence of MG are higher than previously estimated, and the total societal costs of MG are substantial. Our findings demonstrate that productivity losses, and the value of LLY and HRQoL constitute a considerable proportion of the total societal costs.